BRAF and metastatic malignant neoplasm: The phase II “VE basket” trial evaluating the BRAF TKI vemurafenib in BRAF-mutated metastatic cancers showed mixed results with a response rate of 12% (one patient out of eight) in BRAF-mutated metastatic cholangiocarcinoma [82].